About this trial
Knee osteoarthritis (KOA) is a common joint disease that causes chronic pain and limits daily activities. Current treatments, such as painkillers or surgery, have limitations like side effects or high costs. This study will test whether a safe, non-drug intervention-inspiratory muscle training (breathing exercises against resistance)-can reduce knee pain in people with KOA. The training may work by lowering inflammation and improving the body's nervous system control of pain.
We plan to enroll 80 patients aged ≥55 years with confirmed KOA and frequent knee pain. Participants will be randomly assigned to either an 8-week inspiratory muscle training program (5 sessions per week, with gradually increasing resistance) or a sham (very low resistance) training program. Neither the patients nor the researchers assessing the outcomes will know who is in which group.
The main outcome is change in knee pain measured by a visual analog scale (VAS). Secondary outcomes include blood markers of inflammation (TNF-α, IL-6, IL1β), physical function, WOMAC score (a KOA-specific questionnaire), activity level, sleep quality, and quality of life. To explore underlying mechanisms, we will also measure heart rate variability (HRV) as an indicator of autonomic nervous system function, and brain functional connectivity in the prefrontal cortex using functional near-infrared spectroscopy (fNIRS). These mechanistic assessments will be performed at baseline and at the end of 8-week intervention. Additional follow-up assessments for clinical outcomes will be done at 3 and 6 months after the training ends. We will also record any side effects or adverse events.
This study will provide high-quality evidence on whether inspiratory muscle training is an effective and safe complementary treatment for knee pain in people with knee OA, and will offer new insights into the mechanisms underlying its analgesic effects.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Aged 55 years or older.
Knee osteoarthritis (Kellgren-Lawrence grade ≥ 2).
Knee pain (Visual Analogue Scale, VAS ≥ 3) on the most days in the past month.
Able to walk independently without assitive devices.
Disqualifiers
History of knee replacement surgery, meniscus surgery, or ligament surgery.
Received corticosteroid injection within the previous three weeks.
Diagnosed with rheumatoid arthritis.
Unstable angina, recent myocardial infarction, uncontrolled cardiac arrhythmia, or severe heart failure.
Trial design
Parallel
Treatments tested in this trial
Inspiratory muscle training
Other interventionParticipants will perform home-based inspiratory muscle training using a threshold-loading device (POWERbreathe Medic Plus). Training is conducted 5 times per week for 8 weeks. The initial inspiratory load is set at 50% of the individual's maximum inspiratory pressure (MIP), measured weekly at the study site. The load is progressively increased to 80% MIP over the first 4 weeks and maintained at 80% MIP for the remaining 4 weeks. Each session consists of 40-60 breaths. Adherence is monitored via an electronic training log and weekly on-site visits. This protocol is individualized, progressive, and home-based, distinguishing it from fixed-load or supervised-only breathing interventions.
Treatment groups
Trial outcomes
Primary outcomes
Visual analogue scale
Self-rated pain intensity of knee (0-10), "0" indicate no pain, "10" indicate worst pain.
Secondary outcomes
Western Ontario and McMaster Universities Osteoarthritis Index
Patient-reported outcomes in symptoms and function, total scores range from 0-96, the higher scores indicating the worse symptom and function.
Serum levels of inflammatory markers
Systemic inflammation
Heart rate variability
Vagus nerve activity
Prefrontal cortex activity
Functional near-infrared spectroscopy was used to assess prefrontal cortex activity
Other outcomes
Adherence
Adherence was calculated from logbooks as completed versus prescribed sessions
Adverse events
Adverse events were defined as any symptom or abnormal sign during training and graded by the Common Terminology Criteria for Adverse Events (CTCAE v6.0, 2025): Mild: resolved with rest, no medical intervention; Moderate: require minimal medical intervention (e.g., analgesics); Severe: requires medical attention or hospitalization (e.g., clinic visit)
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: